Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alunacedase alfa
- Development stage
- Phase 2
- Lead developer
- Apeiron Biologics
- Modality
- Peptides, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Alunacedase alfa is a recombinant, soluble glycosylated form of human angiotensin-converting enzyme 2 (ACE2). It acts as a decoy receptor for the SARS-CoV-2 spike protein, preventing viral entry into host cells. Additionally, it enzymatically converts angiotensin II (Ang1–8), which promotes inflammation and vasoconstriction, into angiotensin 1–7 (Ang1–7), which has vasodilatory and anti-inflammatory effects. This dual mechanism underlies its investigation for acute respiratory distress syndrome (ARDS) and COVID-19-related lung injury. The drug is being developed primarily by Apeiron Biologics and was previously investigated by GlaxoSmithKline under the code name GSK2586881[1][3][4][5][7].
- Brand names
- Alunacedase alfa
- Other names
- Recombinant Human Angiotensin-Converting Enzyme 2
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on alunacedase alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alunacedase alfa.